



**12 January 2007**

**Announcement to the Singapore Exchange**

**LMA FILES MAIN COURT ACTION AGAINST AMBU FOR PATENT  
INFRINGEMENT IN THE NETHERLANDS**

Mainboard-listed LMA International NV (“LMA”), the global leader in the development and marketing of the LMA™ range of supraglottic airway management devices, has enhanced its action against Ambu BV (“Ambu”) in The Netherlands by substituting the preliminary injunction action that it filed in November with a main patent infringement action.

The main action, which was filed yesterday, has been taken through wholly-owned subsidiary, The Laryngeal Mask Company Limited, and relates to the infringement of LMA’s European Patent No. EP 1119386B1 by Ambu in The Netherlands.

Commenting on these developments, Michael Ashton, Group President and Chief Executive Officer of LMA, said “There has been no change in our overall strategy regarding infringements of our intellectual property, or against Ambu in Holland, where we remain convinced of the merits of our case. The conversion of our preliminary injunction application into a main action allows us to more vigorously pursue our action and protect our rights.”

**LMA International NV**  
PO Box 862, Osprey House, Old Street, Jersey, Channel Islands JE4 2ZZ

**ENDS**

---

**FOR FURTHER INFORMATION, PLEASE CONTACT:**

Maria Gianoutsos, IP Consultant, LMA International NV, +44 (0)1923 841756  
Jeffrey Fang, Gavin Anderson & Company, Singapore, +65 9838 5636

**NOTES:**

**LMA International NV**

Incorporated in the Netherlands Antilles in 1998, LMA was listed on the Singapore Exchange in March 2005. LMA designs, develops, markets and distributes medical equipment, principally the LMA™ range of supraglottic airway management devices. These devices are used by physicians to allow respiration, provide ventilation to, and support the airway of patients undergoing surgical procedures and life-saving interventions. Since its first product, the LMA-Classic™, was approved by the FDA for use in the United States in 1991, LMA's growth has been driven by the development of innovative products, geographic expansion, and increased customer awareness of the LMA™ airway as an alternative airway management device. LMA has established a leading position in this growing market.

LMA has an office in Jersey, Channel Islands, and subsidiaries in Singapore, Germany and San Diego, California. Through its 50 percent joint venture in LMA Urology Limited, the Group has a subsidiary in Switzerland to design, manufacture and distribute the LMA StoneBreaker™. DBS Bank and Credit Suisse were the Joint Global Coordinators and Joint Bookrunners for the Initial Public Offering of shares in LMA.

**LMA™ Airways**

For over 20 years, The Laryngeal Mask Company Limited has been making advances in airway design and technology which have impacted directly on patient safety and comfort. British anaesthetist Dr Archie Brain designed the first LMA™ airway in 1988. Since then, LMA™ airways have been used over 200 million times around the world and are supported by over 2,500 published references. The LMA™ airway has become the most well-known and respected supraglottic airway device worldwide, with a full range of products designed for specialist clinical needs including routine anaesthesia, PPV, ENT surgery, the difficult airway and emergency situations.

**LMA Patent Portfolio**

LMA has an extensive patent portfolio that protects the key products in the LMA™ range, as well as new products currently under development. The Company's portfolio comprises an estimated 315 granted and pending patents worldwide, the majority of which have a significant unexpired term. Of the Company's granted patents, the earliest expiry date is 2008, and the latest is around 2025.